Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
about
Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human Interactome.Functional amyloids: interrelationship with other amyloids and therapeutic assessment to treat neurodegenerative diseases.Poly-N-methylated Aβ-Peptide C-Terminal fragments (MEPTIDES) reverse the deleterious effects of amyloid-β in rats.Withdrawal of Antidementia Drugs in Older People: Who, When and How?Discrimination between patients with mild Alzheimer's disease and healthy subjects based on cerebral blood flow images of the lateral views in xenon-enhanced computed tomography.
P2860
Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Mild versus moderate stages of ...... linesterase inhibitor therapy.
@ast
Mild versus moderate stages of ...... linesterase inhibitor therapy.
@en
type
label
Mild versus moderate stages of ...... linesterase inhibitor therapy.
@ast
Mild versus moderate stages of ...... linesterase inhibitor therapy.
@en
prefLabel
Mild versus moderate stages of ...... linesterase inhibitor therapy.
@ast
Mild versus moderate stages of ...... linesterase inhibitor therapy.
@en
P2860
P1476
Mild versus moderate stages of ...... linesterase inhibitor therapy.
@en
P2093
Carina Wattmo
Åsa K Wallin
P2860
P2888
P356
10.1186/S13195-016-0174-1
P407
P577
2016-02-17T00:00:00Z
P6179
1004034832